DexCom Inc

$59.06
(as of Apr 4, 9:48 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for DexCom Inc

Stock Price
$59.06
Ticker Symbol
DXCM
Exchange
NASDAQ

Industry Information for DexCom Inc

Sector
Healthcare
Industry
Medical Devices

Company Description for DexCom Inc

Country
USA
Full Time Employees
10,200

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Fundamentals for DexCom Inc

Market Capitalization
$26,718,171,136
EBITDA
$817,699,968
Dividends per Share
P/E Ratio
47.99
Forward P/E Ratio
33.44
Earnings per Share
$1.42
Earnings per Share Estimate Next Year
Profit Margin
14.29%
Shares Outstanding
392,107,008
Percent Owned by Insiders
0.41%
Percent Owned by Institutions
96.12%
52-Week High
52-Week Low

Technical Indicators for DexCom Inc

50-Day Moving Average
200-Day Moving Average
RSI
26.15
2.98

Analyst Ratings for DexCom Inc

Strong Buy
15
Buy
5
Hold
5
Sell
0
Strong Sell
0

News About DexCom Inc

Apr 3, 2025, 8:30 AM EST
SAN DIEGO, April 03, 2025--(BUSINESS WIRE)--DexCom, Inc. See more.
Apr 3, 2025, 5:09 AM EST
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks See more.
Apr 1, 2025, 8:59 AM EST
Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. See more.
Apr 1, 2025, 8:00 AM EST
Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage for Dexcom’s continuous glucose monitoring systems. See more.